Dr Reddy’s must warn Celgene of plans to sell generic blockbuster cancer drug

Bristol-Myers Squibb 2021-12-07 2:55 pm By Cindy Cameronne | Sydney

Please login to bookmark

Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer drug Revlimid in Australia.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au